New therapy shows promise in challenging blood cancers

Ryvu Therapeutics (WSE: RVU) has revealed encouraging clinical results for its experimental drug romaciclib (RVU120) from two Phase II trials in difficult-to-treat blood cancers. The RIVER-81 trial in acute myeloid leukaemia (AML) and the POTAMI-61 study in myelofibrosis (MF) suggest the therapy could benefit patients with few alternatives.

In RIVER-81, romaciclib combined with venetoclax produced complete remissions in 43% of patients at 150 mg daily. Early data indicate it may help overcome venetoclax resistance in relapsed or refractory AML. The therapy was generally well tolerated, with no new safety concerns.

The POTAMI-61 study tested romaciclib alone or in combination with ruxolitinib in MF patients who had poor responses to JAK inhibitors. Of 14 evaluable patients, 7 achieved meaningful reductions in spleen volume, including one with a 59% reduction, along with improvements in symptom scores.

“Romaciclib continues to show activity in haematologic cancers with high unmet need,” said Hendrik Nogai, MD, Chief Medical Officer. “These results support further development of this first-in-class CDK8/19 inhibitor.”

Additional data from the REMARK study in lower-risk myelodysplastic syndromes and the JASPIS-01 trial of dapolsertib in aggressive B-cell lymphoma were also presented at the American Society of Hematology (ASH) Annual Meeting. Ryvu continues to advance its pipeline of targeted oncology therapies aimed at addressing critical unmet needs in patients.

More information online